Derisking
Developability
Ask for advice
Ensuring optimal developability through advanced derisking approaches
Therapeutic antibodies are the molecules of choice to treat major diseases such as cancer and auto-immunity. They are typically generated from B-cells of an immunized animal, then highly engineered to produce molecules with exquisite characteristics. Based on experience, MImAbs has developed a highly efficient strategy to reduce the risk of failure along the complex journey of therapeutic antibody development. From immunogen design to manufacturing process, MimAbs can identify and address risks very early in the design process. Leveraging the capabilities of the Beacon® platform, key characteristics of antibodies like target specificity, affinity, cross reactivity with analogs from other species are validated as early as day 1 of the process. That approach ensures the effective selection of lead candidates and a fast path to the clinic.
By combining in silico modeling and in vitro surrogate assays early in development (such as cytotoxicity testing on PDX-DC), we provide a comprehensive developability assessment that streamlines lead validation, reduces costly rework, and accelerates decision-making on critical development paths.
Proven know-how
Access to specialized know-how in antibody engineering, manufacturability assessment, functional validation both in vitro and in vivo.
See the serviceExclusive integrated de-risking program
An accelerated pipeline enabling early lead selection, extensive payload comparison, developability assessment, and streamlined progression toward downstream preclinical
proof-of-concept.
Risk-adjusted development of robust preclinical candidates
Leveraging MImAbs’ experience to anticipate challenges in overall developability (hydrophobicity, stability, etc), specificity, efficacy and Pharmacokinetic distribution.
See the serviceOur Key Approaches to De-Risking Biologics Programs
Partnering with MImAbs
can accelerate your progress.
With comprehensive expertise across the entire ADC workflow, we guide you through every step.
mAb Generation
From day one, identify the most promising candidate based on required functionalities
mAb Engineering
Leverage in silico studies for clustering, identifying liabilities, and assessing developability
Bioproduction
Advanced QC & mammalian expression
Functionnal characterization
In-house biophysical characterization combined with pre-CMC expertise
Examples of ADC applications
Talk to one of our expert
Need expert support in ADC ?
Contact MimAbs to discuss your project, our team will support you in the scientific study and strategic development planning of your project.
Contact an expert